Tetraspanin CD151 as an emerging potential poor prognostic factor across solid tumors: a systematic review and meta-analysis

Ping Zeng, Yin-Hua Wang, Meng Si, Jin-Hua Gu, Ping Li, Pei-Hua Lu _ and Min-Bin Chen

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:5592-5602. https://doi.org/10.18632/oncotarget.13532

Metrics: PDF 742 views  |   HTML 1058 views  |   ?  


Ping Zeng1,*, Yin-Hua Wang1,2,*, Meng Si3, Jin-Hua Gu1, Ping Li1, Pei-Hua Lu4, Min-Bin Chen1

1Department of Radiotherapy and Oncology, Kunshan First People’s Hospital Affiliated to Jiangsu University, Kunshan 215300, Jiangsu Province, China

2Department of Oncology, Changshu Second People’s Hospital Affiliated to Yangzhou University, Changshu 215500, Jiangsu Province, China

3Department of Neurology, the Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu Province, China

4Department of Medical Oncology, Wuxi People’s Hospital of Nanjing Medical University, Wuxi 214023, Jiangsu Province, China

*These authors contributed equally to this work and should be considered co-first authors

Correspondence to:

Pei-Hua Lu, email: lphty1_1@163.com

Min-Bin Chen, email: cmb1981@163.com

Keywords: CD151, solid tumors, prognosis, overall survival, disease-free survival

Received: June 08, 2016     Accepted: November 02, 2016     Published: November 23, 2016


Tetraspanin CD151, also known as PETA-3 or SFA-1, has been reported to predict prognosis in various solid tumors. Yet, the results of these studies remained inconclusive. Here, we performed this meta-analysis of relevant studies published on the topic to quantitatively evaluate the clinicopathological significance of CD151 in solid tumors. The relevant articles were identified via searching the PubMed, Web of Science and Embase database. The pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CI) of overall survival (OS) and disease-free survival (DFS) were calculated to evaluate the prognostic value of CD151 expression in patients with solid tumors. A total of 19 studies involving 4, 270 participants were included in the study, we drew the conclusion that CD151 overexpression was associated with statistically significant poor OS (pooled HR = 1.498, 95% CI = 1.346-1.667, P<0.001) and poor DFS (pooled HR = 1.488, 95% CI = 1.314-1.685, P<0.001). Furthermore, the subgroup analysis revealed that the associations between CD151 overexpression and the outcome endpoints (OS or TTP) were significant within the Asian region and European, as well in patients with breast cancer or gastric cancer. Taken together, the incorporative HR showed CD151 overexpression was associated with poor survival in human solid tumors. CD151 could be a valuable prognosis biomarker or a potential therapeutic target of solid tumors.

PII: 13532